GeoVax Labs, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited consolidated results. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies. Its principal clinical programs include GEO-CM04S1, a COVID-19 vaccine in Phase 2 trials, and Gedeptin for advanced head and neck cancer.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.43 million | $2.82 million |
| General and administrative expense | $1.46 million | $1.45 million |
| Total operating expenses | $5.88 million | $4.27 million |
| Net loss | $5.85 million | $4.04 million |
| Net loss per share, basic and diluted | $2.47 | $2.30 |
| Net cash used in operating activities | $5.68 million | $3.76 million |
At March 31, 2024, cash and cash equivalents were $768,859, versus $6.45 million at December 31, 2023. Working capital was a deficit of $441,529, compared with positive working capital of $4.37 million at year-end. Current liabilities were $3.30 million; total assets were $3.36 million and stockholders’ equity was $54,275. The balance sheet reports no debt. No investing or financing cash flows occurred during Q1. Profit margins are not meaningful because the company had no revenue.
Changes from the comparable period
- Net loss increased by $1.81 million. R&D expense rose 57% ($1.61 million), primarily due to clinical-trial manufacturing materials and related costs, personnel, and preclinical research.
- G&A expense was nearly unchanged, increasing $5,928 (0.4%).
- Interest income fell to $32,949 from $232,698, which the company attributed to lower cash balances.
- Operating cash use increased by $1.92 million year over year.
Outlook, developments, and risks
- Management states that existing cash is insufficient to fund planned operations beyond Q2 2024 without additional financing. The filing says substantial doubt exists about the company’s ability to continue as a going concern; management expects to secure funding, but its plans do not alleviate that doubt.
- On May 10, 2024, after quarter-end, the company issued unsecured bridge notes with $150,000 aggregate principal to directors and senior management. The notes have a 10% original issue discount, bear 15% annual interest, and mature within six months or shortly after a qualifying equity offering of at least $5 million, whichever occurs first.
- GeoVax is pursuing equity or debt financing, grants/contracts, and strategic partnerships. It reported advanced discussions with BARDA regarding a potential Project NextGen award, but no award is assured.
- Management expects R&D spending to increase as programs advance and provides no cost or completion estimates for research programs. Failure to obtain funding could force delays, reductions, or termination of development, or licensing of product rights; equity financing could dilute shareholders.
- GEO-CM04S1’s healthy-booster Phase 2 enrollment was completed in September 2023; the company reported positive interim safety and immune-response findings in February 2024. Gedeptin enrollment closed in January 2024, with study completion expected in Q3 2024 and possible follow-on FDA discussions.
- The company announced completion of manufacturing transfer and scale-up to Oxford Biomedica, including release of the first GEO-CM04S1 lot using the commercial manufacturing platform. Clinical, regulatory, manufacturing, and financing outcomes remain uncertain.
- A one-for-fifteen reverse stock split became effective January 31, 2024, alongside a reduction in authorized common shares from 600 million to 150 million. Shares outstanding were 2,308,309 at March 31, 2024; the company also reported 1,826,247 warrants outstanding.
- Operating lease payments are $140,292 for the remainder of 2024 and $192,708 for 2025; either party may terminate the lease with 180 days’ notice. License-related contingent payments are not determinable.
Most important facts for investors to verify
- Whether GeoVax secures sufficient financing to continue operations beyond Q2 2024, and the terms and dilution or debt costs of any financing.
- Whether BARDA makes a Project NextGen award and whether the company can convert its discussions into funding.
- Clinical-trial progress and results for GEO-CM04S1 and Gedeptin, including the anticipated Gedeptin study completion and any subsequent FDA plans.
- Cash burn, working-capital needs, clinical manufacturing commitments, and the company’s continuing going-concern assessment.